近日，2025年12月在港股成功上市的翰思艾泰-B(03378.HK)发布的公告显示，因个人职业规划原因，张 辉先生已辞任公司联席公司秘书、副总经理、首席财务官、董事会秘书职务。董事会委任肖女士担任公 司首席财务官、董事会秘书，自2026年2月8日起生效。根据服务合约，肖女士将收取基本薪酬每年人民 币七十五万元及酌情花红，酌情花红将由董事会经参考（其中包括）肖女士的表现及本集团的整体表现 不时厘定。 新任首席财务官肖婕妤女士简历如下： 肖婕妤女士，43岁，肖女士于2005年6月毕业于华中农业大学，获得植物保护专业学士学位。其亦于 2008年6月获得上海医药工业研究院药理学硕士学位。其于2017年6月获得中国证券投资基金业协会的基 金业从业证书。 肖女士于2024年3月1日加入该集团并获委任为董事。其于2024年8月22日调任为非执行董事。于加入该 公司之前，其自2012年6月至2015年6月曾担任武汉光谷创投私募基金管理有限公司的高级投资经理，负 责投资及企业融资工作。自2016年2月至2016年10月，其曾担任华源证券股份有限公司（前称为九州证 券股份有限公司）湖北分公司的副经理，负责投资银行、投资及融资工 ...

厦门港务公告称，拟通过发行股份及支付现金，向厦门国际港务购厦门集装箱码头集团70%股权，并向 不超35名特定对象募配套资金。2026年2月13日，公司收到证监会批复，同意其发行796,854,165股股份 购买相关资产，以及发行股份募集配套资金不超35亿元，批复自下发日起12个月内有效。公司将在规定 期限内办交易相关事宜并及时披露信息。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 特別決議案 | 票數(%) | | | | --- | --- | --- | --- | | | 贊成 | 反對 | 棄權 | | 審議及批准於有關期間授予董事會一 | 98,771,940 | 400 | 0 | | 般授權以購回H股 | (99.9996%) | (0.0004%) | (0.0000%) | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技（武漢）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3378） 公告 於2026年2月12日舉行的臨時股東大會投票表決結果 茲提述翰思艾泰生物醫藥科技（武漢）股份有限公司（「本公司」））日期為2026年1月27 日的通函（「通函」）。除非文義另有所指，本文中所使用的詞彙與通函所定義者具有 相同涵義。 本公司於2026年2月12日（星期四）上午十時正假座中國湖北 ...

執行董事 張發明博士 （董事會主席） 李其翔博士 劉敏先生 肖婕妤女士 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技（武漢）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3378） 董事名單與其角色及職能 翰思艾泰生物醫藥科技（武漢）股份有限公司（「本公司」）董事會（「董事會」）成員（「董 事」）載列如下： 畢紅鋼博士 陳奇峰先生 王世雄先生 張瓊光博士 董事會設有三個董事委員會。下表提供該等董事委員會的成員資料。 非執行董事 李健博士 獨立非執行董事 | | 董事委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | | 審核委員會 | 提名委員會 | 薪酬委員會 | | 張發明博士 | | | C | | | 李其翔博士 | | | | M | | 劉敏先生 | | | | | | 肖婕妤女士 | | | M | | | 李健博士 | | | | | | 畢紅鋼博士 | | | M | M | | 陳奇峰先生 | | C | M | | | 王世雄先生 | | M | | C ...

Core Insights - The announcement of the first patient enrollment in the Phase I clinical trial of HX111, a novel OX40-targeted antibody-drug conjugate (ADC), marks a significant milestone for the company and highlights its innovative capabilities in the ADC space [1][2] - The company has developed a dual-antibody pipeline in cell immunotherapy, showcasing its comprehensive R&D strength and high-value product matrix [1][4] ADC Development - HX111 is the first OX40-targeted ADC to enter clinical trials globally, addressing a significant technical gap in the field [2] - The drug utilizes a monoclonal antibody targeting OX40 and a potent microtubule inhibitor MMAE, specifically binding to OX40 molecules overexpressed on tumor cells, leading to effective apoptosis in resistant tumors [2] Dual-Antibody Pipeline - The company has developed two key dual-antibody candidates, HX009 and HX044, targeting CD47, which is crucial for overcoming blood toxicity issues associated with first-generation therapies [3] - HX009 employs a strategy of strong PD-1 binding and weak CD47 binding to enhance T cell activity against tumors, while HX044 is the first CTLA-4×CD47 dual antibody in clinical trials, targeting Treg cells in the tumor microenvironment [3] R&D Team and Innovation - The company's R&D strength is supported by a top-tier team with deep academic and industry experience, covering all critical aspects of the drug development process [4] - The innovative achievements stem from a thorough understanding of biological mechanisms and continuous iteration of core technologies, creating significant barriers to entry and first-mover advantages [4] Market Potential - The market for HX111, targeting relapsed/refractory tumors, presents a substantial unmet need, while the dual-antibody candidates focus on immune therapy resistance and multi-cancer treatment, representing a market potential worth hundreds of billions [4] - As clinical trials progress and commercialization expectations rise, the company's performance growth is expected to be robust [4] Future Outlook - The ongoing clinical trials for HX111, HX009, and HX044 are anticipated to further highlight the company's multi-technology synergy, leading to increased market recognition of its core value [5] - The company's commitment to innovation is setting a benchmark for Chinese biotech firms and establishing a foundation for long-term, high-quality growth [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 翰思艾泰生物醫藥科技（武漢）股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03378 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 136,218,830 | RMB | | 0.1 RMB | | 13,621,883 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 136,218,830 | RMB | | 0.1 RMB | | 13,621,883 ...

董事会进一步宣布，因个人职业规划原因，张辉先生(张先生)已辞任本公司联席公司秘书、副总经理、 首席财务官、董事会秘书职务，自2026年2月8日起生效。 本公司另一名联席公司秘书李健威先生(李先生)，将继续担任本公司的公司秘书。本公司已调任肖女士 为其总部的主要联络人，负责维持与李先生的日常沟通。 翰思艾泰-B(03378)发布公告，因工作调整，肖婕妤女士(肖女士)由非执行董事获调任为执行董事，自 2026年2月8日起生效。 于肖女士调任执行董事生效后，彼将不再担任审核委员会的成员，自2026年2月8日起生效。自2026年2 月8日起，独立非执行董事张琼光博士已获委任为审核委员会的成员。 董事会进一步宣布，委任肖女士担任公司首席财务官、董事会秘书，自2026年2月8日起生效。根据服务 合约，肖女士将收取基本薪酬每年人民币七十五万元及酌情花红，酌情花红将由董事会经参考(其中包 括)肖女士的表现及本集团的整体表现不时厘定。 ...

Core Viewpoint - The company has initiated a Phase I clinical trial for its self-developed candidate drug HX111, an OX40-targeted antibody-drug conjugate (ADC), aimed at treating relapsed/refractory lymphoma and solid tumors, with the first patient successfully dosed recently [1] Group 1: Drug Development - HX111 is designed to bind with high affinity and specificity to the OX40 molecule on the surface of tumor cells, facilitating efficient internalization and subsequent release of a potent payload that induces tumor cell apoptosis [1] - The OX40 molecule is highly expressed in certain lymphomas and solid tumors, which currently lack effective treatment options, indicating a significant unmet clinical need [1] - HX111 is the first OX40-targeted ADC drug to enter clinical trials globally, representing a first-in-class (FIC) innovation in this therapeutic area [1] Group 2: Market Opportunity - The field of OX40-targeted therapies is still in the early exploratory stage, providing HX111 with a significant first-mover advantage [1] - The development of HX111 has the potential to address a critical gap in the treatment landscape for these types of tumors [1]

Core Viewpoint - The company has initiated a Phase I clinical trial for its self-developed candidate drug HX111, an OX40-targeted antibody-drug conjugate (ADC), aimed at treating relapsed and refractory lymphoma and solid tumors, with the first patient successfully dosed recently [1] Group 1: Drug Development - HX111 specifically binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity [1] - The drug efficiently enters tumor cells through endocytosis, where it is cleaved by lysosomal proteases to release a potent payload, inducing apoptosis in tumor cells [1] - OX40 is highly expressed in certain lymphomas and solid tumors, which currently lack effective treatment options, indicating a significant unmet clinical need [1] Group 2: Market Position - HX111 is the first OX40-targeted ADC drug to enter clinical trials globally, representing a first-in-class (FIC) innovation [1] - The field of OX40-targeted therapies is still in the early exploratory stage, giving HX111 a significant first-mover advantage [1] - The drug has the potential to fill a therapeutic gap in the treatment of these types of tumors in the future [1]

Core Viewpoint - The company has initiated a Phase I clinical trial for its self-developed candidate drug HX111, an OX40-targeted antibody-drug conjugate (ADC), aimed at treating relapsed/refractory lymphoma and solid tumors, with the first patient successfully dosed recently [1] Group 1: Drug Development - HX111 specifically binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity [1] - The drug efficiently enters tumor cells through endocytosis, where it is cleaved by lysosomal proteases to release a potent payload, inducing tumor cell apoptosis [1] - OX40 is highly expressed in certain lymphomas and solid tumors, which currently lack effective treatment options, indicating a significant unmet clinical need [1] Group 2: Market Position - HX111 is the first OX40-targeted ADC drug to enter clinical trials globally, marking it as a first-in-class (FIC) product [1] - The field of OX40-targeted therapies is still in the early exploratory stage, providing HX111 with a significant first-mover advantage [1] - The drug has the potential to fill a therapeutic gap in the treatment of these types of tumors [1]